New York Attorney General Letitia James and Emergent BioSolutions have reached an agreement to increase access to an opioid overdose nasal spray device.
Emergent, maker of the opioid overdose reversal nasal spray Narcan (naloxone), previously had a contract with the manufacturer of the device used to administer the drug. This may have kept companies working on their own opioid overdose drugs from using the device, the AG said.
“I’m proud to announce that, starting today, additional companies will be able to gain access to these nasal spray devices,” said James. “With more companies able to access this easy-to-use technology, our hope is that we can reduce the number of opioid overdose deaths.”